Biotech Capital Stack Analyzer
Who funds what risk, at which stage, and who gets paid back first — mapped against the cognitive capital hierarchy of the Neural Capital OS.
Seniority Hierarchy
↑ First Claim · Last Loss ↑Common Equity
Founders · Team · Early Believers
Preclinical → Seed
Preferred Equity
Seed / Series A–C VCs · Strategics
Series A → C
Capital Instruments
Risk Drivers
Neural Capital Analog
QTAC₇ scores — structured claims on verified cognitive capacity
Royalty / Structured Equity
Crossover · Royalty Finance · Strategic Partners
Phase II → Pre-Approval
Mezzanine Debt / Preferred
Credit Funds · Venture Debt · Equipment Finance
Late-Stage → Commercial
Senior Project Debt
Banks · Credit Funds · Infrastructure Lenders
Post-Approval → Scale
Capital Mix by Development Stage
Equity share vs debt capacity as risk profile evolves
- Equity Share
- Debt Capacity
Risk Lever Profile by Stage
Five biotech-specific risk dimensions across development timeline
- Tech Risk
- Clinical
- Manufacturing
- Regulatory
- Commercial
Technology Risk
Core biology validity, in vitro → in vivo path, platform robustness
Clinical Risk
Phase I/II/III success probability, safety profile, trial design
Manufacturing Risk
Lab → pilot → GMP scale-up viability, yield economics, COGS
Regulatory Risk
Pathway clarity (CGT vs small mol), approval timing, compliance
Commercial Risk
Reimbursement, pricing power, competitive durability, biosimilar threats